
-
Delcath Systems Inc NasdaqCM:DCTH Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Location: 566 Queensbury Avenue, New York, NY, 12804, United States | Website: https://www.delcath.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
536.3M
Cash
58.9M
Avg Qtr Burn
-1.724M
Short % of Float
2.78%
Insider Ownership
2.61%
Institutional Own.
45.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Approved Quarterly sales | |
CHEMOSAT® Details Uveal melanoma | Phase 2 Update | |
HEPZATO™ Details Liver-Dominant Metastatic Breast Cancer | Phase 2 Initiation | |
HEPZATO™ Details Metastatic colorectal cancer | Phase 2 Initiation | |
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma | Failed Discontinued |